Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62,162,717
-
Total 13F shares
-
47,169,803
-
Share change
-
-4,550,615
-
Total reported value
-
$397,624,990
-
Put/Call ratio
-
14%
-
Price per share
-
$8.43
-
Number of holders
-
127
-
Value change
-
-$36,850,674
-
Number of buys
-
67
-
Number of sells
-
63
Institutional Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q3 2022
As of 30 Sep 2022,
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) was held by
127 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
47,169,803 shares.
The largest 10 holders included
STATE STREET CORP, RTW INVESTMENTS, LP, FARALLON CAPITAL MANAGEMENT LLC, BlackRock Inc., VANGUARD GROUP INC, FMR LLC, Point72 Asset Management, L.P., JOHNSON & JOHNSON, Bain Capital Life Sciences Investors, LLC, and MORGAN STANLEY.
This page lists
128
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.